Anvisa orders withdrawal of batches of counterfeit hormone and stolen oncology medication due to health risk

The National Health Surveillance Agency (Anvisa) ordered the recall and seizure of several batches of a growth hormone that was counterfeited, as well as a medicine used to treat cancer that had been diverted from cargo in Europe and illegally introduced into Brazilian territory. The official decision of the regulatory agency was published in the Official Gazette of the Union (DOU) on Monday, June 15th.
With the determination, the commercialization, distribution, import and any type of use of these products throughout the national territory is prohibited. The measure aims to protect public health, since the origin and integrity of these medicines are compromised, posing a serious risk to patients.
Counterfeit Criscy units are identified by Anvisa
As determined by Anvisa, adulterated units of Criscy, a crucial medicine formulated with somatropin, were found. This hormone is widely used in the treatment of patients, both children and adults, who suffer from growth hormone deficiency, highlighting the seriousness of falsification for the health of these individuals.
Detailed analysis of Criscy packaging revealed several inconsistencies compared to the original product, including differences in manufacturing and expiration dates. Additionally, a batch number (22030133) was identified that did not correspond to any authentic record.
Cristália Produtos Químicos Farmacêuticos, the company that holds the official registration of the medicine in Brazil, was the first to report the irregularities. The company confirmed the existence of counterfeit and replicated units, warning that the unknown origin of these products irreversibly compromises their quality, safety and therapeutic efficacy.
Lot of Kimmtrak, for cancer treatment, was stolen in Europe
The regulatory agency also established the mandatory recall of Kimmtrak lot 4A010AA27. This particular drug is prescribed for the treatment of a rare form of cancer that affects the eyes, making any gaps in its supply chain particularly critical for patients.
According to information released by Anvisa, the batch in question was stolen during the transport of cargo on the European continent. After the theft, units of the medicine began to be sold and used in a completely irregular and clandestine manner within Brazil.
The complaints and data relating to the Kimmtrak product were provided by Medison Pharma Brasil Produtos Farmacêuticos Ltda., the company responsible for obtaining and maintaining the drug’s registration in the country, collaborating with authorities to mitigate risks.






